T1	Participants 129 187	advanced gastric or gastroesophageal cancer adenocarcinoma
T2	Participants 221 290	For patients with advanced gastric or gastroesophageal cancer (AGGEC)
T3	Participants 545 557	445 patients
T4	Participants 517 536	multinational trial
